Sanofi India Ltd.

NSE: SANOFI BSE: 500674 SECTOR: Pharmaceuticals & Drugs  51k   267   39

5919.50
+29.20 (0.50%)
NSE: 07 Oct 03:57 PM

Price Summary

Today's High

₹ 5925

Today's Low

₹ 5832

52 Week High

₹ 8449

52 Week Low

₹ 5757.85

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

13632.98 Cr.

Enterprise Value

12082.68 Cr.

No. of Shares

2.3 Cr.

P/E

13.93

P/B

9.37

Face Value

₹ 10

Div. Yield

8.27 %

Book Value (TTM)

₹  631.65

CASH

1550.3 Cr.

DEBT

0 Cr.

Promoter Holding

60.4 %

EPS (TTM)

₹  425.09

Sales Growth

1.88%

ROE

44.65 %

ROCE

57.98%

Profit Growth

97.74 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Sanofi India Ltd.

Allegra Avil Combiflam Clexane Cardace Daonil Lantus Taxotere Soframycin Arava Lasix

Index Presence

The company is present in 18 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year1.88%
3 Year2.19%
5 Year4.55%

Profit Growth

1 Year97.74%
3 Year35.38%
5 Year25.43%

ROE%

1 Year44.65%
3 Year28.04%
5 Year23.83%

ROCE %

1 Year57.98%
3 Year37.83%
5 Year33.73%

Debt/Equity

0

Price to Cash Flow

24.4

Interest Cover Ratio

699.666666666667

CFO/PAT (5 Yr. Avg.)

0.940380682711971

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2022 60.4 0
Mar 2022 60.4 0
Dec 2021 60.4 0
Sep 2021 60.4 0
Jun 2021 60.4 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 35.3824590227838% for the Past 3 years.
  • Company has been maintaining healthy ROE of 28.0353012098799% over the past 3 years.
  • Company has been maintaining healthy ROCE of 37.8329998024332% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 699.666666666667.
  • The Company has been maintaining an effective average operating margins of 22.8613831204867% in the last 5 years.
  • Company’s PEG ratio is 0.142475959521512.
  • The company has an efficient Cash Conversion Cycle of -32.1667444576898 days.
  • The company has a high promoter holding of 60.4%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 14.2672786906757.

 Limitations

  • The company has shown a poor revenue growth of 2.18703494602148% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022
Net Sales 789.1 754.5 687.9 707 699.3
Total Expenditure 542 555.7 560.7 512.5 538.2
Operating Profit 247.1 198.8 127.2 194.5 161.1
Other Income 17.1 14.7 16.3 24.4 15.7
Interest 0.5 0.5 0.4 0.4 0.4
Depreciation 21.1 14.3 10.9 10.9 10.6
Exceptional Items 0 489.2 0 118.1 0
Profit Before Tax 242.6 687.9 132.2 325.7 165.8
Tax 64.3 158.1 41.8 87.3 45.4
Profit After Tax 178.3 529.8 90.4 238.4 120.4
Adjusted EPS (Rs) 77.52 230.35 39.3 103.65 52.35

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021
Net Sales 2463.6 2770.8 3070.6 2901.9 2956.6
Total Expenditure 1926.4 2147.9 2405.3 2188.8 2194.3
Operating Profit 537.2 622.9 665.3 713.1 762.3
Other Income 80.7 90.3 94.1 89.8 74.6
Interest 1.1 0.7 0.3 1.8 1.8
Depreciation 102.2 102.7 99.9 82.2 66.7
Exceptional Items 0 0 -59.3 -41.7 489.2
Profit Before Tax 514.6 609.8 599.9 677.2 1257.6
Tax 188.6 229.2 185.7 199.6 313.2
Net Profit 326 380.6 414.2 477.6 944.4
Adjusted EPS (Rs.) 141.74 165.48 180.09 207.65 410.61

Balance Sheet (All Figures are in Crores.)

Particulars Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021
Equity and Liabilities
Share Capital 23 23 23 23 23
Total Reserves 2003.4 2196.2 2419.3 2096 2202.6
Borrowings 0 0 0 0 0
Other N/C liabilities 1335.1 1357.1 1124.1 1280.3 1038.9
Current liabilities 962.4 1193 1673.5 1694.1 2290.8
Total Liabilities 4323.9 4769.3 5239.9 5093.4 5555.3
Assets
Net Block 769 732.8 498.7 464.1 334.1
Capital WIP 24.4 16.4 12.7 6.3 8.9
Intangible WIP 5.7 4.7 4.7 3.7 3.9
Investments 0.2 0.2 0 0 0
Loans & Advances 1712.9 1843.8 1617.2 1773.1 1523.8
Other N/C Assets 7.2 9.7 7.2 5.6 5.5
Current Assets 1804.5 2161.7 3099.4 2840.6 3679.1
Total Assets 4323.9 4769.3 5239.9 5093.4 5555.3
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021
Profit from operations 514.6 609.8 599.9 677.2 1257.6
Adjustment 38.6 35.8 78.4 65 -482
Changes in Assets & Liabilities 80.3 -27.6 -37.7 62.2 68.1
Tax Paid -198.4 -244.1 -228.3 -193.3 -284.9
Operating Cash Flow 435.1 373.9 412.3 611.1 558.8
Investing Cash Flow -78.7 -73.1 65.7 276.4 630.8
Financing Cash Flow -188.4 -197.2 -183.2 -810 -849
Net Cash Flow 168 103.6 294.8 77.5 340.6

Corporate Actions

Investors Details

PARTICULARS Jun 2021% Sep 2021% Dec 2021% Mar 2022% Jun 2022%
Promoters 60.40 60.40 60.40 60.40 60.40
hoechst gmbh - 60.37 60.37 60.37 60.37
hoechst gmbh 60.37 - - - -
sanofi - 0.02 0.02 0.02 0.02
sanofi 0.02 - - - -
PARTICULARS Jun 2021% Sep 2021% Dec 2021% Mar 2022% Jun 2022%
Investors 39.60 39.60 39.60 39.60 39.60
life insurance cor... 4.90 4.90 5.94 5.95 5.95
aditya birla sun l... 2.70 2.92 2.93 2.85 2.91
aditya birla sun l... - - - - -
aberdeen global in... 1.08 - - - -
uti-mastershare un... 1.64 1.25 1.15 1.12 1.13
sbi magnum midcap ... - - - - -
uti-mnc fund - - - - -
nippon life india ... 1.78 2.17 2.20 2.10 2.10
icici prudential p... 1.36 1.86 2.14 1.94 1.67
reliance capital t... - - - - -
nippon life india ... - - - - -
l&t mutual fund tr... - - - - -
bajaj allianz life... 1.06 1.08 1.13 1.44 1.61
hdfc life insuranc... 1.07 1.16 1.17 1.15 1.15
hdfc life insuranc... - - - - -
general insurance ... - - - - 1.04
llp 0.31 0.31 0.31 0.22 0.22
iepf 0.15 0.16 0.16 0.16 0.16

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Sanofi India informs about loss of share certificate6 Oct 2022, 12:12PM Sanofi India informs about certificate 6 Oct 2022, 10:39AM Sanofi India - Quaterly Results26 Jul 2022, 5:25PM Sanofi India - Quaterly Results26 Jul 2022, 5:25PM Sanofi India - Quaterly Results26 Jul 2022, 5:25PM Sanofi India informs about loss of share certificate16 May 2022, 4:57PM Sanofi India reports 63% rise in Q1 net profit26 Apr 2022, 3:25PM Sanofi India - Quaterly Results26 Apr 2022, 2:27PM Sanofi India - Quaterly Results26 Apr 2022, 2:27PM Sanofi India - Quaterly Results26 Apr 2022, 2:27PM Sanofi India informs about newspaper publication5 Apr 2022, 2:52PM Sanofi India informs about outcome of board meeting24 Feb 2022, 11:59AM Sanofi India reports 27% fall in December quarter net profit 24 Feb 2022, 11:45AM Sanofi India - Quaterly Results23 Feb 2022, 6:36PM Sanofi India - Quaterly Results23 Feb 2022, 6:36PM Sanofi India - Quaterly Results23 Feb 2022, 6:36PM Sanofi India informs about loss of share certificate29 Oct 2021, 4:43PM Sanofi India informs about details of loss of share certificate6 Oct 2021, 12:44PM Sanofi India informs about details of loss of share certificate 15 Sep 2021, 3:48PM Sanofi India informs about disclosures of related party transactions24 Aug 2021, 12:16PM Sanofi India gets nod to transfer Nutraceuticals business to Universal Nutriscience 28 Jul 2021, 10:40AM Sanofi India informs about loss of share certificates15 Jul 2021, 3:57PM Sanofi India informs about issuance of duplicate share certificates23 Jun 2021, 4:39PM Sanofi India informs about board meeting 14 Apr 2021, 12:02PM Sanofi India informs about certificate7 Apr 2021, 4:45PM Sanofi India informs about investor webinar presentation17 Mar 2021, 5:07PM Sanofi India informs about board meeting8 Feb 2021, 11:02AM Sanofi India informs about loss of share certificates19 Jan 2021, 5:15PM Sanofi India informs about loss of share certificate11 Dec 2020, 2:54PM Sanofi India informs about loss of share certificate28 Oct 2020, 10:45AM Sanofi India informs about loss of share certificate26 Oct 2020, 11:11AM Sanofi India informs about loss of share certificate22 Oct 2020, 1:46PM Sanofi India informs about disclosure6 Oct 2020, 1:44PM Sanofi India informs about appointment of CFO5 Oct 2020, 5:11PM Sanofi India informs about loss of share certificates25 Aug 2020, 4:23PM Sanofi India board to consider unaudited financial results15 Jul 2020, 1:15PM Sanofi India launches awareness initiative ‘Allergy Free’ 30 Jun 2020, 12:48PM

Sanofi India Stock Price Analysis and Quick Research Report. Is Sanofi India an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Sanofi India and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 558.8 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Sanofi India has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Sanofi India , the EPS growth was 97.7386707195975 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Sanofi India has OPM of 25.7829939795711 % which is a good sign for profitability.
     
  • ROE: Sanofi India have a healthy ROE of 44.647204822125 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Sanofi India

X